Clinical trials: Wegener Granulomatosis
Lupus Nephritis, Immunoglobulin A Nephropathy
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis …
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- RUBY-3 (NCT05732402)
- Testing
- Povetacicept
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 72 people
- Sponsor
- Alpine Immune Sciences, Inc.
EGPA - Eosinophilic Granulomatosis With Polyangiitis, HES - Hypereosinophilic Syndrome
The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome
The purpose of this study is to collect clinical, laboratory, and instrumental data from patients with eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome, which will then be analyzed using artificial…
- Trial name
- NCT07275190
- Testing
- Blood draw for the laboratory assessment
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Rheumatoid Arthritis, Pemphigus Vulgaris
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently FDA approved (e.g., Rheumatoid Arthritis (RA), Pemphigus Vulgaris…
- Conditions
- Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
- Trial name
- IRIS-RD-01 (NCT06581562)
- Testing
- AB-101, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- IRIS Research and Development, LLC
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS)
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
Naltrexone is an FDA approved drug (for alcoholism) that has found widespread use "off-label" to treat pain and improve quality of life at much lower doses than are used for the approved indication.
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis
- Trial name
- LoDoNaVasc (NCT03482479)
- Testing
- Naltrexone Hydrochloride
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- University of Pennsylvania
EGPA - Eosinophilic Granulomatosis With Polyangiitis
Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis
RACEMATE is a phase 2b, multicentre, randomised, double-blinded, placebo-controlled study designed to explore the efficacy and mechanism of action of tezepelumab in adults with eosinophilic granulomatosis with polyangiitis (EGPA).
- Trial name
- RACEMATE (NCT06230354)
- Testing
- Tezepelumab
- Where
- 12 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Imperial College London
Inflammation, Vasculitis
Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis
This study will collect fluid and tissue samples from the bronchi (air passages to the lungs) of patients with Wegener's granulomatosis for laboratory examination.
- Conditions
- Inflammation, Vasculitis, Wegener's Granulomatosis
- Trial name
- NCT00001541
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vasculitis, Wegener's Granulomatosis
Etanercept to Treat Wegener's Granulomatosis
This study will examine the use of etanercept (also called Enbrel or TNFR:Fc) in patients with Wegener's granulomatosis, a type of vasculitis (blood vessel inflammation).
- Trial name
- NCT00001901
- Testing
- Etanercept
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vasculitis, Wegener's Granulomatosis
Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
The purpose of this study is to assess the safety, tolerance, and immunologic effects of interleukin-10 (IL-10), in patients with Wegener's granulomatosis.
- Trial name
- NCT00001761
- Testing
- Interleukin-10
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Eosinophilic Asthma, EGPA - Eosinophilic Granulomatosis With Polyangiitis
Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils
Introduction: The etiology and therapy of eosinophilic lung diseases are still poorly understood. For individual forms of disease, such as eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA), new…
- Conditions
- Eosinophilic Asthma, EGPA - Eosinophilic Granulomatosis With Polyangiitis, Samter Triad, HES - Hypereosinophilic Syndrome
- Trial name
- PROMETHEos (NCT04538937)
- Testing
- no intervention
- Where
- Austria
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Systemic Lupus Erythematosus, Lupus Nephritis
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002 injection (CD19-BCMA CAR-T cells) that patients…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- BAH242 (NCT06350110)
- Testing
- CD19- BCMA CAR-T cells
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Essen Biotech
ANCA + Vasculitides Relapsing Either Under Corticosteroid, and Immunosuppressant Therapies or After One Year
Intravenous Immunoglobulin After Relapse in Vasculitis
The aim of this study is to study the efficacy of intravenous immunoglobulins for inducing remission in patients relapsing of systemic vasculitides.
- Conditions
- ANCA + Vasculitides Relapsing Either Under Corticosteroid, and Immunosuppressant Therapies or After One Year, Post Treatment.
- Trial name
- NCT00307658
- Testing
- Intravenous immunoglobulins (human immunoglobulins G)
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.
- Trial name
- CLIPS (NCT06512883)
- Testing
- Benralizumab
- Where
- 15 sites in United States, Brazil and 8 more
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Benralizumab Effectiveness in EGPA
This is a multicenter, retro-prospective observational study evaluating the effectiveness and safety of benralizumab in adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) in a real-world setting.
- Trial name
- BELONG-EGPA (NCT07815886)
- Testing
- Benralizumab 30 mg/ml
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- European EGPA Study Group
Asthma, EGPA(Eosinophilic Granulomatosis With Polyangiitis)
FASENRA Regulatory Postmarketing Surveillance in Korea
As part of a post approval commitment, the MFDS has requested a study to characterize safety in patients who are treated with FASENRA for severe eosinophilic asthma and/or eosinophilic granulomatosis with polyangiitis (EGPA) by…
- Trial name
- FASENRA rPMS (NCT05091333)
- Where
- 5 sites in South Korea
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Granulomatosis With Polyangiitis (Wegener's Granulomatosis)
Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
This is a phase IV, single-center, randomized, placebo-controlled pilot study that will evaluate the efficacy of rituximab at inducing otolaryngologic remission in GPA patients with active otolaryngologic disease.
- Trial name
- RENTGPA (NCT02626845)
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Hospital for Special Surgery, New York
Eosinophilic Granulomatosis With Polyangiitis
Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)
The purpose of this study is to compare mepolizumab-based regimen to conventional therapeutic strategy for remission induction in patients with Eosinophilic Granulomatosis with Polyangiitis.
- Trial name
- E-merge (NCT05030155)
- Testing
- Mepolizumab, cyclophosphamide/azathioprine
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Vasculitis, Wegener's Granulomatosis
Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions
This study will examine the safety and effectiveness of the drug mycophenolate mofetil (MPM) in treating Wegener's granulomatosis and related inflammatory vessel diseases.
- Trial name
- NCT00001764
- Testing
- Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Reslizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5.
- Trial name
- RITE (NCT02947945)
- Testing
- Reslizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Jewish Health
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA)
Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)
This observational study aims to evaluate the long-term effectiveness and safety of mepolizumab 300 mg/4 weeks in adults with eosinophilic granulomatosis with polyangiitis (EGPA) in the European real-life setting.
- Trial name
- Mepo LTF (NCT07591753)
- Testing
- Mepolizumab 300 mg
- Where
- Italy
- Volunteers
- 591 people
- Sponsor
- European EGPA Study Group